AZU1 and prostate carcinoma: A variety of mRNA isoforms of TACC2 have been reported, including a 3.8-kb isoform termed anti-zuai-1 gene (AZU-1), and 4.2-kb and 9.7-kb major isoforms29; the isoform AZU-1 was originally considered a tumor suppressor gene29 but recent studies reported increased expression of TACC2 in breast cancer patients with poor prognosis56 and in prostate cancer patients with poor survival rate57.